FDA Week - 04/12/2019

In final guidance setting out when it will require a REMS . . .

FDA Rebuffs PhRMA, Weighs Off-Label Use In Deciding If REMS Needed

April 05, 2019
FDA will consider the extent to which a drug’s intended population is expected to use the product for off-label uses when deciding whether to require a risk mitigation program for certain drugs, a policy the brand industry had alleged may exceed the agency’s statutory authority. The decision is tucked into a final guidance issued Thursday (April 4) that lists six factors FDA will consider when weighing whether a Risk Evaluation and Mitigation Strategy (REMS) is needed to ensure a drug’s...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.